Division of Trillium Therapeutics Inc.
Latest From Trillium Therapeutics
Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.
AstraZeneca paid $240 million for rights to Moderna’s RNA therapeutics. Argon Medical acquired Angiotech’s interventional business for $362.5 million. PIPEs accounted for 31% of the $976 million in biopharma financing. FOPOs, on the other hand, dominated the $523 million in device fundraising.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on licensing agreements between universities or other research institutions and biopharma, medtech, and diagnostic start-ups.
- Large Molecule
- Therapeutic Areas
- Gynecological, Urological
- Transplantation Technologies Inc.
- North America
- Parent & Subsidiaries
- Trillium Therapeutics Inc.
- Senior Management
Niclas Stiernholm, PhD, CEO
Bob Uger, PhD, VP, R&D
Eric L Sievers, MD, CMO
- Contact Info
Phone: (416) 595-0627
96 Skyway Ave.
Toronto, M9W 4Y9
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.